Report Store Get Proposal

Home Blog Notizia 38

Notizia - Recent Pharma, Healthcare and Biotech Happenings

recent-pharma-news-update-happenings-for-amgen-rodeo-novartis-organon-alydia-forma

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels

Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, a privately-held biopharmaceutical company based in Seattle, which develops small-molecule therapies to enhance regeneration and repair of several tissues. Rodeo's 15-PGDH program is a robust strategic fit with Amgen's inflammation portfolio and efforts to develop first-in-class therapeutics for patients. Under terms of the deal, Amgen will acquire all outstanding shares of Rodeo in exchange for a USD 55 million upfront payment and future contingent milestone payments potentially worth up to a...

Explore More...

cancer

Clinical

FDA

AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval

Default Blog Image

Outset Medical captures; Wright Medical Group to takeover Cartiva; Y-mAbs Therapeutics prepares for IPO; Biotech boom remunerates analysts

transthyretin amyloidosis

Notizia

Entasis

AZ dragout Entasis; Sierra remunerates Gilead; Principia raises; Harbour BioMed and Kelun pen deal

transthyretin amyloidosis

Kalydeco got approved; Opdivo for SCLC; FDA approved for pain relief; GC4419 obviates

cancer

KEY CLINICAL OUTCOMES

FDA

Regulatory

astellas

Commercial

Therapeutics

The Business Cocktail(Therapeutics)

Default Blog Image

Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup

Entasis

Progenics got FDA Approval; Curcumin to cancer cells

Default Blog Image

GeneDx secures $92M funding; BioTech Innovations partners with Novartis for R&D collaboration

Therapeutics

Business Cocktail

astellas

Commercial Outcomes – Novartis

cancer

Key Clinical Outcomes- 30/07/2018

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly